<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">28916114</PMID>
      <DateCompleted>
        <Year>2018</Year>
        <Month>06</Month>
        <Day>12</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2018</Year>
        <Month>06</Month>
        <Day>12</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1773-0597</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>40</Volume>
            <Issue>8</Issue>
            <PubDate>
              <Year>2017</Year>
              <Month>Oct</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal francais d'ophtalmologie</Title>
          <ISOAbbreviation>J Fr Ophtalmol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>[Scleritis and episcleritis].</ArticleTitle>
        <Pagination>
          <StartPage>681</StartPage>
          <EndPage>695</EndPage>
          <MedlinePgn>681-695</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jfo.2017.04.007</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0181-5512(17)30260-7</ELocationID>
        <Abstract>
          <AbstractText>Episcleritis is generally a benign disease with a self-limited course, while scleritis is a severe ocular condition due to a risk of impaired vision in one-fifth of patients and its association with systemic diseases in one third of them. Infectious scleritis, representing 8 % of the etiologies, is mainly of herpetic origin (varicella zoster and herpes simplex viruses). A systemic autoimmune disease is observed in roughly 30 % of scleritis patients: inflammatory rheumatisms (15 %), firstly rheumatoid polyarthritis, systemic vasculitides (8 %), mainly granulomatosis with polyangiitis (Wegener's) and polychondritis, and less often inflammatory bowel disease and systemic lupus erythematosus. Among the different types of scleritis, a clear distinction exists between necrotizing forms leading to decreased vision in 50 % of the cases and associated with systemic diseases in the vast majority, and non-necrotizing forms (either diffuse or nodular), with a better prognosis. However, recent publications show that necrotizing forms are much less frequent nowadays (around 5 % of the total), probably due to therapeutic innovations and progress made during the last 20 years. The medical management of scleritis requires collaboration between ophthalmologists and internists (or rheumatologists).</AbstractText>
          <CopyrightInformation>Copyright © 2017 Elsevier Masson SAS. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Héron</LastName>
            <ForeName>E</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Service de médecine interne, centre hospitalier national d'ophtalmologie des Quinze-Vingts, 28, rue de Charenton, 75571 Paris cedex 12, France. Electronic address: eheron@15-20.fr.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bourcier</LastName>
            <ForeName>T</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Service d'ophtalmologie, Nouvel hôpital civil, université de Strasbourg, hôpitaux universitaires, BP 426, 67091 Strasbourg, France.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>fre</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <VernacularTitle>Sclérites et épisclérites.</VernacularTitle>
        <ArticleDate DateType="Electronic">
          <Year>2017</Year>
          <Month>09</Month>
          <Day>13</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>France</Country>
        <MedlineTA>J Fr Ophtalmol</MedlineTA>
        <NlmUniqueID>7804128</NlmUniqueID>
        <ISSNLinking>0181-5512</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D001327" MajorTopicYN="N">Autoimmune Diseases</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003941" MajorTopicYN="N">Diagnostic Techniques, Ophthalmological</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015423" MajorTopicYN="Y">Scleritis</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Complication</Keyword>
        <Keyword MajorTopicYN="N">Episcleritis</Keyword>
        <Keyword MajorTopicYN="N">Infection</Keyword>
        <Keyword MajorTopicYN="N">Maladie systémique</Keyword>
        <Keyword MajorTopicYN="N">Scleritis</Keyword>
        <Keyword MajorTopicYN="N">Sclérite</Keyword>
        <Keyword MajorTopicYN="N">Systemic disease</Keyword>
        <Keyword MajorTopicYN="N">Traitement</Keyword>
        <Keyword MajorTopicYN="N">Treatment</Keyword>
        <Keyword MajorTopicYN="N">Épisclérite</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2017</Year>
          <Month>2</Month>
          <Day>22</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2017</Year>
          <Month>4</Month>
          <Day>3</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2017</Year>
          <Month>9</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2018</Year>
          <Month>6</Month>
          <Day>13</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2017</Year>
          <Month>9</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">28916114</ArticleId>
        <ArticleId IdType="doi">10.1016/j.jfo.2017.04.007</ArticleId>
        <ArticleId IdType="pii">S0181-5512(17)30260-7</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
